Fig. S2

Fig. S2

Caged etv2 MO photoactivation at 24 hpf but not at the later stages specifically inhibits thoracic duct formation as analyzed by confocal imaging of fli1a:GFP; TgBAC(prox1a:KalT4-UAS:uncTagRFP) larvae at 5 dpf.

(A-H) Images of the trunk region in the GFP channel (left panels) and enlarged views of the thoracic duct in GFP and RFP channels (A'-H'). DA, dorsal aorta.

(A-D) Caged etv2 MO photoactivation at 24 hpf results in the absence of the thoracic duct. Note the normal vascular patterning and present thoracic duct (arrowhead) in uninjected control and never photoactivated larvae (A,A’,B,B’), abnormal vascular patterning and absent thoracic duct in the early uncaged larvae (shield stage, 6 hpf) (C, C’, asterisks) and normal vascular patterning and absent thoracic duct when Etv2 function was inhibited at 24 hpf (D, D’, asterisks).

(E,F) Injection and photoactivation of the standard control MO and etv2 caging strand mixture does not affect vascular patterning or thoracic duct formation (arrowhead). (E,E’) Standard control MO / etv2 caging strand mixture injected larvae which were not photoactivated; (F,F’) larvae that were photoactivated at 24 hpf.

(G,H) Photoactivation of caged etv2 MO injected embryos at 34 hpf (G,G’) or 48 hpf (H,H’) does not affect thoracic duct formation (arrowheads). Experiment has been replicated at least twice.